Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
| Revenue (Most Recent Fiscal Year) | $8.33M |
| Net Income (Most Recent Fiscal Year) | $-89.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 100.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.26 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1144.97% |
| Net Margin (Trailing 12 Months) | -1144.97% |
| Return on Equity (Trailing 12 Months) | -78.44% |
| Return on Assets (Trailing 12 Months) | -44.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.17 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.09 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.35 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 272.80M |
| Free Float | 262.48M |
| Market Capitalization | $810.20M |
| Average Volume (Last 20 Days) | 2.80M |
| Beta (Past 60 Months) | 0.98 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.78% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |